STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 11, Issue 1, Pages e005627
Publisher
BMJ
Online
2023-01-06
DOI
10.1136/jitc-2022-005627
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
- (2022) Qiwei Wang et al. Nature Communications
- STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models
- (2022) Gilles Berger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis
- (2021) Chee Khoon Lee et al. CANCER
- Understanding and overcoming resistance to PARP inhibitors in cancer therapy
- (2021) Mariana Paes Dias et al. Nature Reviews Clinical Oncology
- Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
- (2021) Marine Bruand et al. Cell Reports
- PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer
- (2021) Antons Martincuks et al. Frontiers in Oncology
- Macrophage targeting in cancer
- (2020) Martha Lopez‐Yrigoyen et al. Annals of the New York Academy of Sciences
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- (2020) Susan M Domchek et al. LANCET ONCOLOGY
- Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance
- (2020) Stephen J. Pettitt et al. Cancer Discovery
- PARP Inhibitors in Cancer Diagnosis and Therapy
- (2020) Chung Ying Chan et al. CLINICAL CANCER RESEARCH
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion
- (2019) Chuan-xia Zhang et al. CELL DEATH AND DIFFERENTIATION
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models
- (2019) Weiqing Jing et al. Journal for ImmunoTherapy of Cancer
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
- (2019) Kalindi Parmar et al. CLINICAL CANCER RESEARCH
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Up-Regulation of CX3CL1 via STAT3 Contributes to SMIR-Induced Chronic Postsurgical Pain
- (2018) Yijia Shen et al. NEUROCHEMICAL RESEARCH
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- 936PDA phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)
- (2018) J-M Lee et al. ANNALS OF ONCOLOGY
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- CSF1R regulates the dendritic cell pool size in adult mice via embryo-derived tissue-resident macrophages
- (2018) Gulce Itir Percin et al. Nature Communications
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2018) Kevin K Lin et al. Cancer Discovery
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- (2018) Ling Ding et al. Cancer Immunology Research
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
- (2018) Roman M. Chabanon et al. JOURNAL OF CLINICAL INVESTIGATION
- Do STAT3 inhibitors have potential in the future for cancer therapy?
- (2017) Andrea L.A. Wong et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Reverse the Resistance to PARP Inhibitors
- (2017) Yevgeniy Kim et al. International Journal of Biological Sciences
- PARP inhibitors plough on
- (2017) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Host STING-dependent MDSC mobilization drives extrinsic radiation resistance
- (2017) Hua Liang et al. Nature Communications
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3–CCL2 Signaling
- (2016) Xuguang Yang et al. CANCER RESEARCH
- Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
- (2016) Joyce F. Liu et al. CLINICAL CANCER RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma
- (2016) Sho Ikeda et al. Oncotarget
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization
- (2014) Charlene M. Downey et al. PLoS One
- Stat3 Inhibition Attenuates Mechanical Allodynia through Transcriptional Regulation of Chemokine Expression in Spinal Astrocytes
- (2013) Xiaodong Liu et al. PLoS One
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More